Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
US11261251B2 · kind B2 · utility
0Cited by
49References
19Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jul 9, 2019 |
| Grant date | Mar 1, 2022 |
| Priority date | — |
| Expiry date | Apr 26, 2040 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-L1, and/or PD-L2 activity (e.g., persistent infections diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.